- Report
- April 2025
- 175 Pages
Global
From €3957EUR$4,490USD£3,475GBP
- Report
- February 2025
- 240 Pages
Global
From €2370EUR$2,690USD£2,082GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1762EUR$2,000USD£1,548GBP
€2203EUR$2,500USD£1,935GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €881EUR$1,000USD£774GBP
€1102EUR$1,250USD£968GBP
- Report
- September 2025
- 250 Pages
Global
From €3957EUR$4,490USD£3,475GBP
- Report
- July 2025
- 175 Pages
Global
From €3957EUR$4,490USD£3,475GBP
- Report
- December 2025
- 485 Pages
Global
From €5155EUR$5,850USD£4,528GBP
- Report
- December 2025
- 483 Pages
Global
From €5155EUR$5,850USD£4,528GBP
- Report
- December 2025
- 377 Pages
Global
From €5155EUR$5,850USD£4,528GBP
- Report
- March 2025
- 150 Pages
Global
From €3393EUR$3,850USD£2,980GBP
€4274EUR$4,850USD£3,754GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2458EUR$2,789USD£2,159GBP
- Report
- November 2025
- 196 Pages
Global
From €4362EUR$4,950USD£3,831GBP
- Report
- June 2025
- 200 Pages
United States
From €2194EUR$2,490USD£1,927GBP
- Report
- August 2022
- 115 Pages
Global
From €3965EUR$4,500USD£3,483GBP
- Report
- August 2024
- 233 Pages
Global
From €5604EUR$6,360USD£4,923GBP
€7006EUR$7,950USD£6,153GBP
- Report
- January 2024
- 395 Pages
Global
From €5287EUR$6,000USD£4,644GBP
€6609EUR$7,500USD£5,805GBP
- Report
- June 2024
- 185 Pages
Global
From €3965EUR$4,500USD£3,483GBP
- Report
- May 2024
- 132 Pages
Global
From €4868EUR$5,524USD£4,276GBP
€5727EUR$6,499USD£5,030GBP
- Report
- May 2024
- 138 Pages
Global
From €4868EUR$5,524USD£4,276GBP
€5727EUR$6,499USD£5,030GBP
- Report
- May 2024
- 135 Pages
Global
From €4868EUR$5,524USD£4,276GBP
€5727EUR$6,499USD£5,030GBP

Epidiolex is a pharmaceutical drug used to treat certain types of epilepsy. It is the first FDA-approved drug derived from cannabidiol (CBD), a component of the cannabis plant. Epidiolex is used to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is classified as a central nervous system (CNS) drug, which are drugs that act on the brain and spinal cord to treat neurological disorders.
Epidiolex is manufactured by GW Pharmaceuticals, a British biopharmaceutical company. It is distributed in the United States by Greenwich Biosciences, a subsidiary of GW Pharmaceuticals. Other companies in the CNS drug market include AbbVie, Allergan, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more